Legend Biotech Corporation (FRA:9LB)
29.80
+8.20 (37.96%)
Last updated: Jun 3, 2026, 5:00 PM CET
Legend Biotech Employees
Legend Biotech had 3,100 employees as of March 31, 2026. The number of employees increased by 200 or 6.90% since the number was last reported on December 31, 2025.
Employees
3,100
Change
200
Growth
6.90%
Revenue / Employee
€318,663
Profits / Employee
€69,972
Market Cap
5.79B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 3,100 | 200 | 6.90% |
| Dec 31, 2025 | 2,900 | 300 | 11.54% |
| Dec 31, 2024 | 2,600 | 800 | 44.44% |
| Dec 31, 2023 | 1,800 | 410 | 29.50% |
| Dec 31, 2022 | 1,390 | 319 | 29.79% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Legend Biotech News
- 6 hours ago - Legend Biotech price target raised to $49 from $31 at UBS - TheFly
- 7 hours ago - Legend Biotech price target raised to $65 from $50 at H.C. Wainwright - TheFly
- 1 day ago - This Is Why Legend Biotech Stock (LEGN) Was Up Today - TipRanks
- 1 day ago - Legend Biotech rises 29.5% - TheFly
- 1 day ago - Legend Biotech presents preliminary clinical data for LB2501 at EHA Congress - TheFly
- 1 day ago - Legend's experimental cell therapy shows promise in blood cancer patients - Reuters
- 1 day ago - Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL) - GlobeNewsWire
- 2 days ago - Legend Biotech presents first-in-human LB2102 results in solid tumors - TheFly